CF PharmTech (HKSE:02652) Total Equity: HK$1,622.1 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02652 CF PharmTech Inc HKSE:02652
15 GF Score
Price HK$17.35
! 5 Warning Signs
View Full Analysis

What is CF PharmTech Total Equity?

CF PharmTech HKSE:02652 +0.81% 15 Total Equity is HK$1,622.1 Mil as of Dec. 2025. GuruFocus rates HKSE:02652 with a GF Score™ of 15/100. The stock has 5 warning signs investors should review.

CF PharmTech's total equity for the quarter that ended in Dec. 2025 was HK$1,622.1 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

CF PharmTech Total Equity Historical Data

* Premium members only.

The historical data trend for CF PharmTech's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CF PharmTech Total Equity Chart

CF PharmTech Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Equity
962.53 995.36 1,002.85 1,622.10

CF PharmTech Semi-Annual Data
Dec22 Dec23 Dec24 Dec25
Total Equity 962.53 995.36 1,002.85 1,622.10
HKSE:02652
15GF Score
CF PharmTech Inc HKSE:02652
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CF PharmTech Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

CF PharmTech's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1962.282-340.18
=1,622.1

CF PharmTech's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1962.282-340.18
=1,622.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of HK$1,622.1 Mil mean?
CF PharmTech (HKSE:02652) has a Total Equity of HK$1,622.1 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for CF PharmTech and its competitors.
Is CF PharmTech's Total Equity too high?
CF PharmTech's current Total Equity is HK$1,622.1 Mil. Overall, CF PharmTech has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does CF PharmTech's Total Equity compare to ZTS?
CF PharmTech's Total Equity of HK$1,622.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for CF PharmTech and its competitors. CF PharmTech's current Total Equity is HK$1,622.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CF PharmTech stock overvalued right now?
CF PharmTech (HKSE:02652) has a current Total Equity of HK$1,622.1 Mil. The current Total Equity is HK$1,622.1 Mil. CF PharmTech's overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For CF PharmTech (HKSE:02652), the current Total Equity is HK$1,622.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CF PharmTech Business Description

Address No. 16, Hucundang Road, Xiangcheng Economic Development District, Jiangsu, Suzhou, CHN
CF PharmTech Inc is engaged in inhalation drug delivery technology. It is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is a specialist in the development of complex inhalation formulations with high barriers to entry, and a platform-based pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, international regulatory filing, and commercialization. Leveraging its self-developed, globally integrated end-to-end capabilities, from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to small interfering RNA (siRNA) nucleic acid delivery platforms. Its therapeutic areas encompass respiratory diseases and nasal diseases.
15GF Score

Get the complete analysis for HKSE:02652

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$17.35
Price